243 related articles for article (PubMed ID: 32376613)
1. Inhibition of SARS-CoV-2 Infection by the Cyclophilin Inhibitor Alisporivir (Debio 025).
Softic L; Brillet R; Berry F; Ahnou N; Nevers Q; Morin-Dewaele M; Hamadat S; Bruscella P; Fourati S; Pawlotsky JM; Ahmed-Belkacem A
Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32376613
[TBL] [Abstract][Full Text] [Related]
2. Interferon-β-1a Inhibition of Severe Acute Respiratory Syndrome-Coronavirus 2 In Vitro When Administered After Virus Infection.
Clementi N; Ferrarese R; Criscuolo E; Diotti RA; Castelli M; Scagnolari C; Burioni R; Antonelli G; Clementi M; Mancini N
J Infect Dis; 2020 Aug; 222(5):722-725. PubMed ID: 32559285
[TBL] [Abstract][Full Text] [Related]
3. Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle.
Salgado-Benvindo C; Thaler M; Tas A; Ogando NS; Bredenbeek PJ; Ninaber DK; Wang Y; Hiemstra PS; Snijder EJ; van Hemert MJ
Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32513797
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 Pandemic: Time to Revive the Cyclophilin Inhibitor Alisporivir.
Pawlotsky JM
Clin Infect Dis; 2020 Nov; 71(16):2191-2194. PubMed ID: 32409832
[TBL] [Abstract][Full Text] [Related]
5. In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect.
Andreani J; Le Bideau M; Duflot I; Jardot P; Rolland C; Boxberger M; Wurtz N; Rolain JM; Colson P; La Scola B; Raoult D
Microb Pathog; 2020 Aug; 145():104228. PubMed ID: 32344177
[TBL] [Abstract][Full Text] [Related]
6. Lithium for the 2019 novel coronavirus.
Gómez-Bernal G
Med Hypotheses; 2020 Sep; 142():109822. PubMed ID: 32408073
[No Abstract] [Full Text] [Related]
7. SARS-CoV-2 and the safety margins of cell-based biological medicinal products.
Modrof J; Kerschbaum A; Farcet MR; Niemeyer D; Corman VM; Kreil TR
Biologicals; 2020 Nov; 68():122-124. PubMed ID: 32891497
[TBL] [Abstract][Full Text] [Related]
8. [Role of cyclophilin A during coronavirus replication and the antiviral activities of its inhibitors].
Tian L; Liu W; Sun L
Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):605-611. PubMed ID: 32347055
[TBL] [Abstract][Full Text] [Related]
9. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Caly L; Druce JD; Catton MG; Jans DA; Wagstaff KM
Antiviral Res; 2020 Jun; 178():104787. PubMed ID: 32251768
[TBL] [Abstract][Full Text] [Related]
10. Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production.
Phillips S; Chokshi S; Chatterji U; Riva A; Bobardt M; Williams R; Gallay P; Naoumov NV
Gastroenterology; 2015 Feb; 148(2):403-14.e7. PubMed ID: 25305505
[TBL] [Abstract][Full Text] [Related]
11. Ivermectin as a Broad-Spectrum Host-Directed Antiviral: The Real Deal?
Jans DA; Wagstaff KM
Cells; 2020 Sep; 9(9):. PubMed ID: 32942671
[TBL] [Abstract][Full Text] [Related]
12. Viruses harness YxxØ motif to interact with host AP2M1 for replication: A vulnerable broad-spectrum antiviral target.
Yuan S; Chu H; Huang J; Zhao X; Ye ZW; Lai PM; Wen L; Cai JP; Mo Y; Cao J; Liang R; Poon VK; Sze KH; Zhou J; To KK; Chen Z; Chen H; Jin DY; Chan JF; Yuen KY
Sci Adv; 2020 Aug; 6(35):eaba7910. PubMed ID: 32923629
[TBL] [Abstract][Full Text] [Related]
13. Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19).
Yuan S; Chan CC; Chik KK; Tsang JO; Liang R; Cao J; Tang K; Cai JP; Ye ZW; Yin F; To KK; Chu H; Jin DY; Hung IF; Yuen KY; Chan JF
Viruses; 2020 Jun; 12(6):. PubMed ID: 32532085
[TBL] [Abstract][Full Text] [Related]
14. Antiviral activities of mycophenolic acid and IMD-0354 against SARS-CoV-2.
Kato F; Matsuyama S; Kawase M; Hishiki T; Katoh H; Takeda M
Microbiol Immunol; 2020 Sep; 64(9):635-639. PubMed ID: 32579258
[TBL] [Abstract][Full Text] [Related]
15. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid (PDL) for COVID-19 in vitro and in vivo.
Deng W; Xu Y; Kong Q; Xue J; Yu P; Liu J; Lv Q; Li F; Wei Q; Bao L
Signal Transduct Target Ther; 2020 May; 5(1):66. PubMed ID: 32385228
[No Abstract] [Full Text] [Related]
17. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
Choy KT; Wong AY; Kaewpreedee P; Sia SF; Chen D; Hui KPY; Chu DKW; Chan MCW; Cheung PP; Huang X; Peiris M; Yen HL
Antiviral Res; 2020 Jun; 178():104786. PubMed ID: 32251767
[TBL] [Abstract][Full Text] [Related]
18. The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro.
Okamoto M; Toyama M; Baba M
Antiviral Res; 2020 Oct; 182():104902. PubMed ID: 32739404
[TBL] [Abstract][Full Text] [Related]
19. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
Xiong R; Zhang L; Li S; Sun Y; Ding M; Wang Y; Zhao Y; Wu Y; Shang W; Jiang X; Shan J; Shen Z; Tong Y; Xu L; Chen Y; Liu Y; Zou G; Lavillete D; Zhao Z; Wang R; Zhu L; Xiao G; Lan K; Li H; Xu K
Protein Cell; 2020 Oct; 11(10):723-739. PubMed ID: 32754890
[TBL] [Abstract][Full Text] [Related]
20. Drug Repurposing Study Pinpoints Potential COVID-19 Antivirals.
Abbasi J
JAMA; 2020 Sep; 324(10):928. PubMed ID: 32897326
[No Abstract] [Full Text] [Related]
[Next] [New Search]
